Format

Send to

Choose Destination
J Dtsch Dermatol Ges. 2019 May;17(5):488-491. doi: 10.1111/ddg.13809. Epub 2019 Mar 15.

Management of dupilumab-associated conjunctivitis in atopic dermatitis.

Author information

1
Department of Dermatology and Allergology, University Medical Center, Munich, Germany.
2
Department of Ophthalmology at Mathildenstraße, University Medical Center, Munich, Germany.
3
Munich City Medical Center, Thalkirchner Straße, Munich, Germany.
4
Department of Dermatology and Allergology, University Medical Center, Utrecht, The Netherlands.

Abstract

Since September 2017, the monoclonal antibody dupilumab (Dupixent® ) has been approved in the EU for the treatment of moderate-to-severe atopic dermatitis. By blocking IL-4 and IL-13 signaling pathways, dupilumab improves both objective signs and subjective symptoms of the disease. Blocking of the IL-4aRα subunit leads to improvement of the skin's barrier function and reduction in Th2-mediated inflammation. While the rate of adverse events on dupilumab is generally low, mild-to-moderate conjunctivitis associated with redness as well as a burning and foreign body sensation has been reported in up to 28 % of patients. Treatment options include topical corticosteroids and topical calcineurin inhibitors. The present review highlights the clinical presentation of dupilumab-associated conjunctivitis and addresses pharmacological and non-pharmacological options available for the treatment of this clinically highly relevant condition.

PMID:
30873757
DOI:
10.1111/ddg.13809

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center